A comparison of the frequency of antibodies to cyclic citrullinated peptides using a third generation anti-CCP assay (CCP3) in systemic sclerosis, primary biliary cirrhosis and rheumatoid arthritis
Autor: | Mittermayer Barreto Santiago, M. Khraishi, Kiyomitsu Miyachi, Suzanne S. Taillefer, Maysan Abu-Hakima, Mary J. Bell, David Robinson, Niall Jones, Murray Baron, Marie Hudson, Peter Docherty, Janet Markland, E. Sutton, Janet E. Pope, Sharon LeClercq, Denise L. Smith, Marvin J. Fritzler, Jean-Pierre Mathieu |
---|---|
Rok vydání: | 2007 |
Předmět: |
Male
musculoskeletal diseases medicine.medical_specialty Arthritis Enzyme-Linked Immunosorbent Assay Peptides Cyclic Arthritis Rheumatoid Primary biliary cirrhosis Rheumatology Antigen Internal medicine Humans Medicine Fluorescent Antibody Technique Indirect skin and connective tissue diseases Autoantibodies Scleroderma Systemic biology Liver Cirrhosis Biliary business.industry Autoantibody IIf General Medicine Middle Aged medicine.disease Rheumatoid arthritis Immunology biology.protein Female Antibody business |
Zdroj: | Clinical Rheumatology. 27:77-83 |
ISSN: | 1434-9949 0770-3198 |
DOI: | 10.1007/s10067-007-0656-4 |
Popis: | The objective was to investigate the frequency of anti-cyclic citrullinated peptides (CCP) antibodies in systemic sclerosis (SSc) and primary biliary cirrhosis (PBC), utilizing a new "third generation" anti-CCP ELISA (anti-CCP3) kit and a conventional anti-CCP2 assay. Patients with PBC, SSc, RA, and normal controls were included in the study. Serum samples were screened for autoantibodies by indirect immunofluorescence (IIF), antibodies to CCP by a second- and third-generation ELISA, antibodies to "scleroderma" antigens (CENP B, Scl-70, PM/Scl and fibrillarin-Scl-34) by a line immunoassay (LIA), and IgM RF by ELISA. The frequency of anti-CCP2 antibodies in SSc and PBC samples was 14.8% (11/74) and 6.2% (5/80), respectively, and the frequency of anti-CCP3 antibodies in SSc was 13.5% (10/74) and in PBC was 3.7% (3/80). By comparison, in the RA group the frequency of anti-CCP3 and anti-CCP2 antibodies was 79.1% (38/48) and 77% (37/48), respectively. Anti-CCP3 ELISA had a sensitivity, specificity, and positive and negative likelihood ratios (LR) of 79% (95% confidence interval [CI] = 64-89%), 93% (95% CI = 88-96%), 11.8 (95% CI = 6.8-20.3), and 0.22 (95% CI = 0.12-0.38), respectively. By comparison, the anti-CCP2 assay had a sensitivity, specificity, and positive and negative LRs of 77% (95% CI = 62-87), 90% (95% CI = 85-94), 8.3 (95% CI = 5.2-13.2), and 0.25 (95% CI = 0.15-0.42), respectively. In patients with SSc, there was an association of anti-CCP2 antibodies with the presence of arthritis, but there was no association of anti-CCP2 or anti-CCP3 with anti-CENP B, anti-Scl 70, or RF. This study confirmed the high specificity and sensitivity of both anti-CCP assays for the diagnosis of RA. The presence of anti-CCP antibodies in SSc was only correlated with the presence of arthritis. |
Databáze: | OpenAIRE |
Externí odkaz: |